Content about Boehringer Ingelheim Pharmaceuticals

June 4, 2013
Boehringer Ingelheim's Robert Belknap honored with 2013 Nexus Award for Lifetime Achievement

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

ARLINGTON, Va. — The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

January 17, 2013
Boehringer Ingelheim Pharmaceuticals starts phase-3 trial of HCV drug

Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

BI Pharmaceuticals is conducting the "HCVerso" trial of an HCV drug that combines faldaprevir, the experimental compound BI 207127 and ribavirin. The company has established trial sites in more than 25 states.

October 9, 2012
Building the ACO

New, holistic models for integrated, patient-centered care are emerging from the fog of health reform almost as fast as you can say “accountable care organization.” But pharmacy and retail clinic operators aren’t waiting for ACOs to fully ripen.

New, holistic models for integrated, patient-centered care are emerging from the fog of health reform almost as fast as you can say “accountable care organization.” But pharmacy and retail clinic operators aren’t waiting for ACOs to fully ripen; they’re forging new alliances with hospital-based health systems and building the kind of continuity-of-care networks that could be a template for the new era of evidence-based medicine and improved patient outcomes.


October 3, 2012
Study: Lilly, BI drug lowers blood sugar in elderly Type 2 diabetes, adult diabetic nephropathy patients

A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

INDIANAPOLIS — A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

September 18, 2012
BI launches Combivent Respimat

Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.

May 24, 2012
Lilly, BI diabetes drug shows greater A1C reduction in African-American adults than placebo, study shows

A drug used to treat Type 2 diabetes produced significant reduction in blood sugar in African-American patients, according to results of a late-stage clinical trial.

RIDGEFIELD, Conn. — A drug used to treat Type 2 diabetes produced significant reduction in blood sugar in African-American patients, according to results of a late-stage clinical trial.

Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced Thursday results of a phase-3 trial of Tradjenta (linagliptin) in which 226 patients with Type 2 diabetes received 5 mg of the drug once per day or placebo.

March 29, 2012
COPD Foundation takes over Drive4COPD campaign leadership from BI

A nonprofit organization focused on chronic obstructive pulmonary disease will take over a COPD awareness campaign from the drug company that started it.

WASHINGTON — A nonprofit organization focused on chronic obstructive pulmonary disease will take over a COPD awareness campaign from the drug company that started it.

The COPD Foundation said it would lead the Drive4COPD campaign — originally started by Boehringer Ingelheim Pharmaceuticals in 2010 to screen people for the disease with the assumption that 24 million Americans may have it but are not aware. BI will continue to provide funding for the program.

November 15, 2011
BI announces more than $350 million in U.S. capital investments

German drug maker Boehringer Ingelheim Pharmaceuticals invested more than $350 million in its U.S. operations this year, the company said Tuesday.

RIDGEFIELD, Conn. — German drug maker Boehringer Ingelheim Pharmaceuticals invested more than $350 million in its U.S. operations this year, the company said Tuesday.

October 10, 2011
FDA approves Boehringer Ingelheim COPD treatment

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

RIDGEFIELD, Conn. — The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 7, 2011
HDMA announces 2011 DIANA winners

The Healthcare Distribution Management Association on Monday awarded eight leading pharmaceutical and consumer product manufacturers through the presentation of its annual Distribution Industry Awards for Notable Achievements in health care.

PHOENIX — The Healthcare Distribution Management Association on Monday awarded eight leading pharmaceutical and consumer product manufacturers through the presentation of its annual Distribution Industry Awards for Notable Achievements in health care.

April 5, 2011
Viramune XR approved by the FDA

The Food and Drug Administration has approved Boehringer Ingelheim Pharmaceuticals' single-pill antiretroviral for HIV-1 patients, BI said Tuesday.

RIDGEFIELD, Conn. — The Food and Drug Administration has approved Boehringer Ingelheim Pharmaceuticals' single-pill antiretroviral for HIV-1 patients, BI said Tuesday.

The FDA approved Viramune XR (nevirapine), a single-pill, once-daily, extended-release formulation of nevirapine for use in combination with other antiretroviral drugs.

March 15, 2011
Pradaxa added to CVS Caremark's, Medco's commercial preferred drug lists

A drug used to prevent stroke in patients with a form of atrial fibrillation has won preferred Tier 2 formulary status with pharmacy benefit managers Medco Health Solutions and CVS Caremark.

RIDGEFIELD, Conn. — A drug used to prevent stroke in patients with a form of atrial fibrillation has won preferred Tier 2 formulary status with pharmacy benefit managers Medco Health Solutions and CVS Caremark.

Boehringer Ingelheim Pharmaceuticals announced Monday that CVS Caremark and Medco had added Pradaxa (dabigatran etexilate mesylate) capsules to their commercial preferred drug lists, and Medco had added the drug to its Part D drug list.

December 9, 2010
Trial data of investigational lung cancer treatment said to extend survival by more than four months

An investigational treatment for lung cancer made by Boehringer Ingelheim Pharmaceuticals extended patients’ survival by more than four months, according to results of a late-stage clinical trial announced Thursday.

RIDGEFIELD, Conn. — An investigational treatment for lung cancer made by Boehringer Ingelheim Pharmaceuticals extended patients’ survival by more than four months, according to results of a late-stage clinical trial announced Thursday.

BI said the phase 2b/3 “LUX-Lung 1” trial of BIBW 2992 (afatinib) showed a fourfold increase in survival among advanced non-small cell lung cancer patients taking the drug versus those taking placebo, whose survival was extended by one month.

March 28, 2009
Health Mart, more than 2,000 strong, building franchise’s drawing power

In late 2008, retail pharmacy’s fastest-growing franchise for independent owner-operators blew past a significant milestone with the addition of its 2,000th drug store member.

Health Mart
President: Tim Canning
Corp. Offices: San Francisco
Number of Members/Stores: 2,000
Web page: www.healthmart.com

In late 2008, retail pharmacy’s fastest-growing franchise for independent owner-operators blew past a significant milestone with the addition of its 2,000th drug store member.